ATE469132T1 - Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung - Google Patents
Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkungInfo
- Publication number
- ATE469132T1 ATE469132T1 AT01952859T AT01952859T ATE469132T1 AT E469132 T1 ATE469132 T1 AT E469132T1 AT 01952859 T AT01952859 T AT 01952859T AT 01952859 T AT01952859 T AT 01952859T AT E469132 T1 ATE469132 T1 AT E469132T1
- Authority
- AT
- Austria
- Prior art keywords
- pyrimidines
- substituted
- alkinyl
- disorders
- neurotrophic action
- Prior art date
Links
- 230000000508 neurotrophic effect Effects 0.000 title 1
- 206010015037 epilepsy Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 208000027232 peripheral nervous system disease Diseases 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22034800P | 2000-07-24 | 2000-07-24 | |
| PCT/US2001/023088 WO2002008205A1 (en) | 2000-07-24 | 2001-07-20 | Substituted 5-alkynyl pyrimidines having neurotrophic activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE469132T1 true ATE469132T1 (de) | 2010-06-15 |
Family
ID=22823191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01952859T ATE469132T1 (de) | 2000-07-24 | 2001-07-20 | Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7205297B2 (de) |
| EP (1) | EP1303495B1 (de) |
| JP (2) | JP5154728B2 (de) |
| AT (1) | ATE469132T1 (de) |
| AU (1) | AU2001273574A1 (de) |
| CA (1) | CA2416442C (de) |
| DE (1) | DE60142236D1 (de) |
| DK (1) | DK1303495T3 (de) |
| ES (1) | ES2346513T3 (de) |
| WO (1) | WO2002008205A1 (de) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100522976C (zh) * | 2002-05-07 | 2009-08-05 | 神经研究公司 | 氮杂环乙炔基衍生物 |
| US7531529B2 (en) | 2003-06-05 | 2009-05-12 | Roche Palo Alto Llc | Imidazole derivatives |
| UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
| KR100717914B1 (ko) | 2003-06-12 | 2007-05-11 | 에프. 호프만-라 로슈 아게 | 글루타메이트 수용체 길항제로서 헤테로아릴-치환된이미다졸 유도체 |
| US20060205740A1 (en) * | 2003-08-14 | 2006-09-14 | Reno Michael J | Chemical compounds |
| DE602004018193D1 (de) * | 2003-12-24 | 2009-01-15 | Astrazeneca Ab | Pyrimidine mit tie2 (tek) aktivität |
| ATE402705T1 (de) * | 2003-12-24 | 2008-08-15 | Astrazeneca Ab | Pyrimidine mit tie2 (tek) aktivität |
| NZ551253A (en) | 2004-06-01 | 2010-07-30 | Hoffmann La Roche | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists |
| US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| CN101084214A (zh) * | 2004-11-17 | 2007-12-05 | 迈卡纳治疗股份有限公司 | 激酶抑制剂 |
| EP1863805A1 (de) * | 2005-02-01 | 2007-12-12 | AstraZeneca AB | Pyrimidinverbindungen mit tie2- (tek-) hemmender wirkung |
| WO2006106721A1 (ja) * | 2005-03-30 | 2006-10-12 | Shionogi & Co., Ltd. | チロシンキナーゼ阻害作用を有するピリミジン誘導体 |
| KR101487027B1 (ko) * | 2005-09-30 | 2015-01-28 | 미카나 테라퓨틱스, 인크. | 치환된 피라졸 화합물 |
| WO2008076883A2 (en) | 2006-12-15 | 2008-06-26 | Abraxis Bioscience, Inc. | Triazine derivatives and their therapeutical applications |
| MY148217A (en) | 2006-12-21 | 2013-03-29 | Hoffmann La Roche | Polymorphs of a mglur5 receptor antagonist |
| EP2166849A4 (de) * | 2007-06-11 | 2010-09-15 | Miikana Therapeutics Inc | Substituierte pyrazol-verbindungen |
| CA2715289C (en) | 2008-02-11 | 2019-12-24 | Rxi Pharmaceuticals Corporation | Modified rnai polynucleotides and uses thereof |
| US8815818B2 (en) | 2008-07-18 | 2014-08-26 | Rxi Pharmaceuticals Corporation | Phagocytic cell delivery of RNAI |
| WO2010012740A1 (en) | 2008-07-29 | 2010-02-04 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
| TW201020245A (en) * | 2008-08-20 | 2010-06-01 | Schering Corp | Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| US8470834B2 (en) | 2008-08-20 | 2013-06-25 | Merck Sharp & Dohme Corp. | AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| EP2326627A1 (de) | 2008-08-20 | 2011-06-01 | Schering Corporation | Substituierte pyridin- und pyrimidinderivate und ihre verwendung bei der behandlung von virusinfektionen |
| ES2439009T3 (es) | 2008-08-20 | 2014-01-21 | Merck Sharp & Dohme Corp. | Derivados de piridina y pirimidina sustituidos con etenilo y su uso en el tratamiento de infecciones virales |
| EP2342340A1 (de) | 2008-09-22 | 2011-07-13 | Rxi Pharmaceuticals Corporation | Rna-interferenz bei hautindikationen |
| WO2010059226A2 (en) | 2008-11-19 | 2010-05-27 | Rxi Pharmaceuticals Corporation | Inhibition of map4k4 through rnai |
| WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
| US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| EP2440053A4 (de) | 2009-06-09 | 2012-10-31 | California Capital Equity Llc | Benzylsubstituierte triazinderivate und ihre therapeutischen anwendungen |
| JP5785940B2 (ja) | 2009-06-09 | 2015-09-30 | アブラクシス バイオサイエンス， エルエルシー | トリアジン誘導体類及びそれらの治療応用 |
| EP2493863B1 (de) | 2009-10-30 | 2015-02-25 | Janssen Pharmaceutica NV | Phenoxy-substitutierte pyrimidine als opioidrezeptormodulatoren |
| US8633183B2 (en) | 2010-01-26 | 2014-01-21 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
| US8618111B2 (en) * | 2010-01-26 | 2013-12-31 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
| CN103200945B (zh) | 2010-03-24 | 2016-07-06 | 雷克西制药公司 | 眼部症候中的rna干扰 |
| RU2615143C2 (ru) | 2010-03-24 | 2017-04-04 | Адвирна | Самодоставляющие PHKi соединения уменьшенного размера |
| EP3560503B1 (de) | 2010-03-24 | 2021-11-17 | Phio Pharmaceuticals Corp. | Rna-interferenz bei dermalen und fibrotischen erkrankungen |
| UA110995C2 (uk) * | 2011-10-07 | 2016-03-10 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як модулятори метаботропного глутаматного рецептора |
| CN106061488B (zh) | 2013-12-02 | 2021-04-09 | 菲奥医药公司 | 癌症的免疫治疗 |
| CN105960265A (zh) | 2013-12-04 | 2016-09-21 | 阿克赛医药公司 | 利用经化学修饰的寡核苷酸处理伤口愈合的方法 |
| WO2015168108A2 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic targeting mdm2 or mycn |
| JP2017514908A (ja) | 2014-05-01 | 2017-06-08 | アールエックスアイ ファーマシューティカルズ コーポレーション | 核酸分子を利用する目の前部における障害の処置のための方法 |
| US10900039B2 (en) | 2014-09-05 | 2021-01-26 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1 |
| US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
| EP3862005A1 (de) | 2015-07-06 | 2021-08-11 | Phio Pharmaceuticals Corp. | Gegen superoxid-dismutase 1 (sod1) gerichtete nukleinsäuremoleküle |
| WO2017070151A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
| US12544344B2 (en) | 2017-04-19 | 2026-02-10 | Phio Pharmaceuticals Corp. | Topical delivery of nucleic acid compounds |
| CN115135765A (zh) | 2019-11-08 | 2022-09-30 | 菲奥医药公司 | 用于免疫治疗的靶向含布罗莫结构域之蛋白4(brd4)的经化学修饰的寡核苷酸 |
| WO2021138537A1 (en) | 2019-12-31 | 2021-07-08 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides with improved systemic delivery |
| WO2023015264A1 (en) | 2021-08-04 | 2023-02-09 | Phio Pharmaceuticals Corp. | Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides |
| JP2024529025A (ja) | 2021-08-04 | 2024-08-01 | フィオ ファーマシューティカルズ コーポレーション | 化学修飾されたオリゴヌクレオチド |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2691655A (en) * | 1952-05-24 | 1954-10-12 | Burroughs Wellcome Co | 2-amino-4-substituted amino-6-aryl pyrimidines and process of preparing same |
| GB951432A (en) * | 1959-03-17 | 1964-03-04 | Wellcome Found | Pyrimidine derivatives and the manufacture thereof |
| US3862190A (en) * | 1972-09-08 | 1975-01-21 | Pfizer | 5-(unsubstituted and substituted phenoxy)-4-amino pyrimidines |
| DK397574A (de) * | 1973-08-24 | 1975-04-28 | Ciba Geigy Ag | |
| GB1523274A (en) | 1974-08-05 | 1978-08-31 | Ici Ltd | Herbicidal compositions containing substituted pyrimidine |
| FR2358148A1 (fr) | 1976-07-12 | 1978-02-10 | Dick Pr | Derives de 2,4-diaminopyrimidines et leur mise en solution en association avec des sulfamides |
| FR2397407A2 (fr) | 1977-07-11 | 1979-02-09 | Dick Pierre | Derives de 2,4-diamino pyrimidines et leur mise en solution en association avec des sulfamides |
| US4508560A (en) * | 1981-11-11 | 1985-04-02 | Ciba Geigy Corporation | Certain pyridylacetylene compounds, compositions containing same and herbicidal methods of use |
| US4663334A (en) * | 1985-12-11 | 1987-05-05 | Mcneilab, Inc. | Heteroaromatic acetylenes useful as antihypertensive agents |
| FI895821A7 (fi) | 1988-12-07 | 1990-06-08 | The Wellcome Foundation Ltd | Farmaseuttisesti aktivisia CNS-yhdisteitä |
| GB9012316D0 (en) * | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| IE912114A1 (en) | 1990-07-02 | 1992-01-15 | Union Pharma Scient Appl | Novel pyrimidine derivatives which are angiotensin ii¹receptor antagonists, their methods of preparation and¹pharmaceutical compositions in which they are present |
| US5075305A (en) * | 1991-03-18 | 1991-12-24 | Warner-Lambert Company | Compound, composition and use |
| US5250532A (en) | 1991-04-11 | 1993-10-05 | Dowelanco | 3,4,N-trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides |
| CZ390992A3 (en) | 1991-04-17 | 1994-03-16 | Pfizer | Pyrimidine derivatives, process of their preparation and use as substances for increase of anti-tumor activity |
| US5336677A (en) | 1991-10-24 | 1994-08-09 | American Home Products Corporation | Substituted aminopyrimidines as antihypertensives |
| GB9125842D0 (en) | 1991-12-04 | 1992-02-05 | Ici Plc | Heterocyclic derivatives |
| EP0674627A1 (de) | 1992-12-18 | 1995-10-04 | The Wellcome Foundation Limited | Pyrimidin-, pyridin-, pteridinon- und indazolderivate als enzyminhibitoren |
| HUT72307A (en) | 1993-03-08 | 1996-04-29 | Eisai Co Ltd | Phosphonic acid derivatives |
| DK0640599T3 (da) | 1993-08-26 | 1998-09-28 | Ono Pharmaceutical Co | 4-Aminopyrimidin-derivater |
| JPH08283246A (ja) | 1994-06-01 | 1996-10-29 | Nippon Soda Co Ltd | ピリミジン誘導体、その製造方法及び有害生物防除剤 |
| CA2217034A1 (en) | 1995-04-03 | 1996-10-10 | Sumitomo Pharmaceuticals Company, Limited | Novel pyrimidine derivatives effective as psychotropic drug and process for the production thereof |
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| US6440965B1 (en) * | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| US6583148B1 (en) * | 1999-04-08 | 2003-06-24 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic substituted pyrimidines |
-
2001
- 2001-07-20 JP JP2002514111A patent/JP5154728B2/ja not_active Expired - Lifetime
- 2001-07-20 AT AT01952859T patent/ATE469132T1/de not_active IP Right Cessation
- 2001-07-20 CA CA2416442A patent/CA2416442C/en not_active Expired - Fee Related
- 2001-07-20 ES ES01952859T patent/ES2346513T3/es not_active Expired - Lifetime
- 2001-07-20 WO PCT/US2001/023088 patent/WO2002008205A1/en not_active Ceased
- 2001-07-20 DE DE60142236T patent/DE60142236D1/de not_active Expired - Lifetime
- 2001-07-20 US US10/333,447 patent/US7205297B2/en not_active Expired - Lifetime
- 2001-07-20 AU AU2001273574A patent/AU2001273574A1/en not_active Abandoned
- 2001-07-20 EP EP01952859A patent/EP1303495B1/de not_active Expired - Lifetime
- 2001-07-20 DK DK01952859.5T patent/DK1303495T3/da active
-
2012
- 2012-06-11 JP JP2012132101A patent/JP2012229218A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20040087789A1 (en) | 2004-05-06 |
| CA2416442A1 (en) | 2002-01-31 |
| ES2346513T3 (es) | 2010-10-18 |
| JP2012229218A (ja) | 2012-11-22 |
| CA2416442C (en) | 2010-06-08 |
| JP2004504386A (ja) | 2004-02-12 |
| EP1303495B1 (de) | 2010-05-26 |
| DK1303495T3 (da) | 2010-09-20 |
| JP5154728B2 (ja) | 2013-02-27 |
| EP1303495A1 (de) | 2003-04-23 |
| WO2002008205A1 (en) | 2002-01-31 |
| DE60142236D1 (de) | 2010-07-08 |
| AU2001273574A1 (en) | 2002-02-05 |
| US7205297B2 (en) | 2007-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE469132T1 (de) | Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung | |
| ATE377592T1 (de) | Neurotropische substituierte pyrimidine | |
| IL225192A (en) | Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury | |
| EA200200183A1 (ru) | Композиция, содержащая трамадол и противосудорожное лекарственное средство | |
| DE122005000044I2 (de) | R-Enantiomer des N-Propargyl-1-Aminoindan zur Behandlung verschiedener Krankheiten und Mesylat, Esylat und Sulfat davon | |
| AP2004003069A0 (en) | 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof. | |
| ATE223399T1 (de) | Quinazolin-4-on ampa antagonisten | |
| TNSN07208A1 (en) | 3,5-DISUBTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d] PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| ECSP055719A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| EA200600294A1 (ru) | [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении | |
| ATE253918T1 (de) | Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel | |
| SG157231A1 (en) | Substituted p-diaminobenzene derivatives | |
| TR200002567T2 (tr) | Glisin naklini önleyiciler. | |
| BRPI0407662B8 (pt) | derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas | |
| MY120976A (en) | 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines | |
| TW200502221A (en) | Novel lactams and uses thereof | |
| DK1463735T3 (da) | Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider | |
| BG108180A (en) | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases | |
| EP1736470A3 (de) | Pyrimidin-Derivate als cb2 Cannabinoid-Rezeptor Modulatoren | |
| BR9803385A (pt) | AtropisÈmeros de 2,3-dissubstituìdo-(5,6)-heteroaril condensado-pirimidin-4-onas. | |
| TW200612969A (en) | 3-β-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof | |
| WO2005046605A3 (en) | Compositions and methods of treating neurological diseases | |
| EA200601607A1 (ru) | Сульфонамидные соединения для лечения нейродегенеративных расстройств | |
| EA200801302A1 (ru) | Композиции и способы лечения нарушений цнс |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |